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Poly(ADP-ribose) polymerase-1 (PARP1) catalyzes the poly(ADP-ribosyl)ation of protein acceptors using NAD+ as
the substrate is now considered as an important target for development of anticancer therapy. PARP1 is known to
be post-translationally modified in various ways including phosphorylation and ubiquitination, but the physiological
role of PARP1 methylation is not well understood. Herein we demonstrated that the histone methyltransferase
SMYD2, which plays critical roles in human carcinogenesis, mono-methylated PARP1. We confirmed lysine 528 to
be a target of SMYD2-dependent PARP1 methylation by LC-MS/MS and Edman Degradation analyses.
Importantly, methylated PARP1 revealed enhanced poly(ADP-ribose) formation after oxidative stress, and
positively regulated the poly(ADP-ribosyl)ation activity of PARP1. Hence, our study unveils a novel mechanism of
PARP1 in human cancer through its methylation by SMYD2.
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Poly(ADP-ribose) polymerase-1 (PARP1) is one of the most
abundant nuclear proteins and catalyzes the transfer of the ADP-
ribose unit from its substrate, NAD+, to some protein acceptors such
as histones and PARP1 itself. Poly(ADP-ribosyl)ation (PARylation) is
one type of post-translational modification, characterized by addition
of ADP-ribose units to glutamic acid, aspartic acid and/or lysine
residues in target proteins by members of the PARP family, and alters
the properties and functions of the proteins. Through its interaction
with partner proteins or/and the poly(ADP-ribosyl)ation of the
proteins, PARP1 is involved in DNA repair, chromatin modification,
transcriptional regulation and genomic stability [1,2]. This PAR-
dependent response network is crucial for both physiological and
pathological responses. As a molecular nick-sensor of DNA breaks,
PARP1 has a crucial role in the organization of the DNA repair
machinery [3]. PARP1 has been shown to play multiple critical roles
in the repair of DNA single-strand breaks (SSBs) and double strand
breaks (DSBs) [4-9]. The activation of PARP1 after DNA damage
recruits enzymes including XRCC1, DNA ligase III and DNA
polymerase β, which are required for DNA repair, to the DNA
damage sites. The involvement of PARP1 in the DNA repair pathwayprompted researchers to investigate the effect of PARP1 inhibition on
DNA-damaging anticancer therapies [10,11]. Inhibition of PARP1
was proven to enhance the cytotoxicity of DNA-damaging agents to
cancer cells [12,13]. Thus, several PARP1 inhibitors have been taken
into the clinical trials [14,15].
Mammalian PARP1 is a 116-kDa protein, comprising anN-terminal
DNA-binding domain including three zinc-binding domains, a central
auto-modification domain, and a C-terminal catalytic domain. The
central auto-modification domain contains several glutamate, aspartate
258 SMYD2-dependent PARP1 Methylation in Cancer Cells Piao et al. Neoplasia Vol. 16, No. 3, 2014and lysine residues as acceptors for its auto(ADP-ribosyl)ation. PARP1
has been reported to be modified through multiple post-translational
modifications, including phosphorylation, acetylation, sumoylation,
ubiquitination and also ADP-ribosylation [16-20]. Meanwhile, the
detailed mechanism how PARP1 activity is controlled by these post-
translational modifications still remains to be elucidated.
The accumulated evidence implicates deregulation of histone
methylation appears to play crucial roles in human carcinogenesis
[21]; for example, many lysine methyltransferases have been shown to
function as oncogenes [22-26]. SET and MYND domain containing
2 (SMYD2) is one of the SMYD methyltransferase family proteins,
containing the SET domain and the MYND domain. SMYD2
methylates histone H3K36 and H3K4, and functions as a
transcriptional regulator in cooperation with the Sin3A and
HDAC1 histone deacetylase complex [27,28]. SMYD2 is also
known to methylate non-histone protein substrates, including
p53 and RB1, and methylated p53 was reported to lose its tumor
suppressive function [29,30]. Overexpression of SMYD2
was observed in various types of cancer [29,31]. Given the
importance of SMYD2 in cancer cell proliferation, SMYD2 become
an attractive drug target that is actively pursued by the pharmaceutical
industry [32].
In this study, we found that SMYD2 methylates PARP1 and
enhances its poly(ADP-ribosyl)ation activity. Our study implicates a
novel mechanism of PARP1 in human carcinogenesis through the
methylation by SMYD2.Materials and Methods
Cell Culture
293T and HeLa cells were from American Type Culture
Collection (ATCC) in 2001 and 2003, and tested and authenticated
by DNA profiling for polymorphic short tandem repeat (STR)
markers (Table W1). Both cell lines were grown in monolayers in
appropriate media: Dulbecco's modified Eagle's medium (D-MEM)
for 293T cells; Eagle's Minimum Essential Medium (E-MEM) for
HeLa cells supplemented with 10% fetal bovine serum and 1%
antibiotic/antimycotic solution (Sigma-Aldrich, St. Louis, MO). We
also generated stable HeLa cell lines constitutively expressing
SMYD2. The pCAGGS-SMYD2-HA or empty pCAGGS-HA
mock vector was transfected into HeLa cells by FuGENE6 (Roche
Applied Science, Penzberg, Germany) according to the manufac-
turer's protocol [22,33], and the antibiotics-resistant clones were
selected with the culture media containing 0.5 mg/ml Geneticin®.
SMYD2 stably expressing HeLa cells were transfected with SMYD2-
specific siRNA duplex (5′- GAAUGACCGGUUAAGAGA-3′), or
siEGFP siRNA duplex (5′- GCAGCACGACUUCUUCAAG-3′) as
a negative control, respectively, by using Lipofectamin RNAiMAX
(Life Technologies, Carlsbad, CA) according to the manufacturer's
recommendations.
In Vitro Methyltransferase Assay
In vitro methyltransferase assays were performed as described
previously [34]. Briefly, 1 μg of His-PARP1 protein was incubated
with 1 μg of His-SMYD2 in 50 mM Tris–HCl (pH 8.8), 1.0 μCi/ml
S-adenosyl-L-[methyl-3H]-methionine (Perkin Elmer, Waltham,
MA) and Milli-Q water for 1 hour at 30°C. After boiling in sample
buffer, the samples were subjected to SDS-PAGE, and visualized by
fluorography [34].Immunoprecipitation
293T cells were seeded at a density of 40% on a 100-mm dish.
After cell attachment, the cells were transfected with expression vector
constructs using FuGENE6, and after 48 h, transfected 293T cells
were washed with PBS and lysed in CelLyticTM M Cell Lysis Reagent
(Sigma-Aldrich) containing complete protease inhibitor cocktail
(Roche Applied Science). Five hundred micrograms of whole-cell
extract were incubated with anti-FLAG M2 agarose (Sigma-Aldrich)
for 1 h at 4°C. After the beads were washed 3 times with 1 ml of TBS
buffer (pH 7.6), the FLAG-tagged proteins bound to the beads were
eluted by boiling in Lane Marker Sample Buffer (Thermo Fisher
Scientific, Waltham, MA). Samples were then subjected to SDS-
PAGE, and detected by western blot.
Immunocytochemistry
Cells fixed by 4% paraformaldehyde were incubated with a
rabbit anti-HA antibody (Y-11, Santa Cruz Biotechnology) at a
1:1000 dilution ratio and a mouse anti-poly(ADP-ribose) (PAR)
monoclonal antibody (Trevigen, Gaithersburg, MD) at a 1:1000
dilution ratio. After washing with PBS (−), cells were stained by
an Alexa Fluor® 488-conjugated anti-mouse secondary antibody
(Life Technologies) and an Alexa Fluor® 594-conjugated anti-
rabbit secondary antibody (Life Technologies) at a 1:1000
dilution ratio. Stained preparations were mounted with VECTA-
SHIELD Mounting Medium with DAPI (Vector Laboratories,
Burlingame, CA).
Mass Spectrometry
The reaction mixture of in vitro methyltransferase assay was
analyzed by nano liquid chromatography–tandem mass spectrometry
(LC-MS/MS) using LCQ Deca XP plus (Thermo Fisher Scientific,
San Jose, CA). The peptides were separated using nano ESI spray
column (100 μm [ID] × 50 mm [L]) packed with a reversed-phase
material (Inertsil ODS-3,3 μm; GL Sciences, Tokyo, Japan) at a flow
rate 200 nl/min. The mass spectrometer was operated in the positive-
ion mode, and the spectra were acquired in a data-dependent MS/MS
mode. The MS/MS spectra were searched against the in-house
database using local MASCOT server (version 2.2.1; Matrix Sciences,
London, United Kingdom). The reaction mixture was desalted and
applied to MALDI-TOF-MS using an Ultraflex (Bruker Daltonik
GmbH, Bremen, Germany).
Edman Degradation
The in vitro methylation product was subjected to Edman
degradation using a Procise HT protein sequencing system (Applied
Biosystems, Foster City, CA).
Amino Acid Analysis
The excised protein bands blotted on the polyvinylidene fluoride
membrane were individually inserted in clean 6 × 32-mmglass tubes
containing 50 pmol of norvaline as internal standard and hydrolyzed
in 6N HCl vapor at 110°C for 20 hours. The hydrolyzed samples
were derivatized in situ by 6-aminoquinolyl-N-hydroxysuccinimidyl
carbamate for fluorophore detection. The 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate amino acids were separated by ion-
pair chromatography on a C18 reversed-phase column (InertSustain
C18HP, 3.0 mm [ID] × 250 mm, 3 μm; GL Sciences, Tokyo, Japan).
Both a laser-induced fluorescence detector (LIF726; GL Sciences)
and a fluorescence detector with Xe flush lamp (G1321A; Agilent
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Figure 1. SMYD2 methylates PARP1 in vitro. (A) Recombinant
PARP1 protein was methylated by SMYD2 in a dose-dependent
manner. An in vitro methyltransferase assay was performed by
using purified His-tagged PARP1 and SMYD2 recombinant pro-
teins. Methylated PARP1 was detected by fluorography. (B) Signals
from methylated PARP1 gradually increased with the increase of
SMYD2. Amounts of loading proteins were confirmed by staining
the MemCodeTM Reversible Protein Stain (Thermo Fisher
Scientific).
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monomethylated Lys [35,36].
PARP1 Enzymatic Activity Assay
PARP1 activities were assayed using the universal colorimetric
PARP assay kit (Trevigen, Gaithersburg, MD) as described
previously [37]. One μg of PARP1 (Alexis, San Diego, CA) was
incubated with 1 μg SMYD2 in 50 mM Tris–HCl (pH 8.8), with
or without 160 nM S-adenosyl-L-methionine (SAM, New England
Biolabs, Ipswich, MA) at 30°C for 4 h respectively. Methylated
PARP1 (with SAM) or unmethylated PARP1 (without SAM) were
loaded into a 96-well plate coated with histone H1, and incubated
with biotinylated poly(ADP-ribose) and nicked DNA (Trevigen)
for 1 hour. All the steps were performed strictly according to the
manufacturer's instructions. Finally, the absorbance was measured
at 450 nm in a spectrometrophotometer.Results
Lysine 528 on PARP1 Is Methylated by SMYD2
Since the physiological function of PARP1 methylation is
unknown, we conducted an in vitro methyltransferase assay of
recombinant PARP1 protein using a variety of recombinant histone
methyltransferases to identify an enzyme(s) that possibly methylates
PARP1 and found that the histone methyltransferase SMYD2 could
methylate PARP1 in a dose-dependent manner (Figure 1A and B).
Subsequently we attempted to identify a methylation site(s) of
PARP1 using in vitro-methylated full-length of PARP1 by liquid
chromatography-tandem mass spectrometry (LC-MS/MS), but failed1.25 11.50 11.75 12.00 12.25 12.50 12.75 13.00 13.25
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Figure 3. Lysine 528 on PARP1 is methylated by SMYD2. (A) The nano-LC-MS/MS spectrum of the specific peptide after in vitro
methyltransferase assay (upper panel) and the theoretical value table of MS fragments (lower panel). The values observed were indicated
in red bold. (B) Chromatograms of Edman degradation. The typical chromatograms of PTH-amino acids standard mixture (left) and α,ε−di
PTH-ε-mono-methyl lysine (right) were shown in lower panel. The Edman degradation chromatogram of 16th residue of the specific
peptides (amino acid residues 513–532) after in vitromethyltransferase assay was shown in upper panel. Asterisk indicated the retention
time of mono-methyl lysine.
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fragments of PARP1. Therefore we focused on amino-acid residues
513–532, which correspond to a critical portion of PARP1 auto-
modification [20] with three lysine residues, Lys 521, Lys 524 and
Lys 528. We synthesized the peptide (513–532) and then performed
an in vitro methyltransferase assay with S-adenosyl-L-[3H-methyl]-
methionine, and found methylation of this peptide (data not shown).
Subsequent matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) analysis showed 14 Da-shift
when it was mixed with SMYD2, implying that the PARP1 peptide is
likely to be mono-methylated (Figure 2A). The mono-methylation on
PARP1 after SMYD2 treatment was also confirmed by amino acid
analysis (Figure 2B).
To further identify a methylation site(s) of PARP1 by SMYD2, we
performed LC-MS/MS analysis and found that lysine 528 to be the
methylation site by SMYD2 (Figure 3A). To validate this result, we
also conducted Edman degradation analysis and confirmed the
methylation of lysine 528 (Figure 3B). We subsequently generated an
antibody against a synthetic peptide with mono-methylation at K528
and confirmed high affinity and specificity of the antibody by ELISA
(Figure 4A). Using this specific antibody, we examined an in vitro
methyltransferase assay using full-length recombinant PARP1 protein
followed by western blot analysis and confirmed the increase of the
methylation specific signal by treatment with SMYD2 (Figure 4B).
To further verify the K528-methylation of PARP1, we prepared andtransfected an expression vector for FLAG-tagged wild-type PARP1
(FLAG-PARP1-WT) or that for FLAG-tagged K528-substituted
PARP1 (FLAG-PARP1-K528A) with an HA-SMYD2 expression
vector into 293T cells. We then precipitated FLAG-proteins by
immunoprecipitation method, and western blot analysis using the
PARP1 K528-methylation antibody detected the signal in the wild-
type PARP1 protein, but not in the K528-substituted PARP1 protein
(Figure 4C). Taken together, SMYD2 can methylate lysine 528 on
PARP1 and this methylation is observed both in vitro and in vivo.
Additionally, since the lysine 528 is highly conserved from Danio
rerio to Homo sapiens, it is likely that this lysine methylation might
have a critical role in the function of PARP1 (Figure 4D).
SMYD2-dependent Methylation Enhances PARP1 Activity
PARP1 poly(ADP-ribosyl)ation activity is well-known to be
involved in multiple cellular processes. To investigate the effect of
methylated PARP1 on its enzymatic activity, recombinant PARP1
was incubated with SMYD2 enzyme in the presence or absence of the
methyl donor S-adenosyl-L-methionine (SAM) at 30°C for 4 h, and
PARP1 activities were measured by the universal colorimetric PARP
assay kit. Consequently, we observed that methylated PARP1 (with
SAM) showed much higher enzymatic activities than unmethylated
PARP1 (without SAM) (Figure 5A). In addition, we incubated
PARP1 with SMYD2 or BSA in the presence of SAM, and analyzed
PARP1 PARylation activities as described in Materials and Methods.
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higher activities (Figure 5B), suggesting that SMYD2 mediated
PARP1 methylation enhanced PARP1 enzymatic activity.
PARP1 Methylation Enhances Cellular Response to Oxidative
DNA Damage
PARP1 is activated in response to DNA damage leading to
auto(ADP-ribosyl)ation and poly(ADP-ribosyl)ation by transferring
the ADP-ribose from NAD+ to other receptor proteins and PARP1
itself, and plays an important role in DNA repair [38]. To elucidate
whether SMYD2-dependent PARP1 methylation influences PARP1
activity in vivo, we examined poly(ADP-ribose) (PAR) synthesis in
cancer cells exposed to H2O2. The HeLa cell lines constitutively
overexpressing SMYD2 were transfected with siSMYD2 or siEGFP,
and cultured for 72 hrs, followed by treatment of cells with 1 mM
H2O2. After 10 minutes, cells were fixed by 4% paraformaldehyde
immediately, and immunostained with a rabbit anti-HA antibody and a
mouse anti-poly(ADP-ribose) (PAR) monoclonal antibody (Trevigen).
SMYD2-depleted cells exhibited the significant reduction of poly(ADP-
ribose) signals compared with those treated with siEGFP (Figure 5C),
implying that poly(ADP-ribosyl)ation activity was affected by knock-
down of SMYD2. Concordantly, SMYD2-overexpressing cells showed
significantly higher poly(ADP-ribosyl)ation activity than control cells
(Figure W1). Additionally, we mixed and seeded the equal numbers of
siSMYD2- or siEGFP-treated HeLa cells, followed by treatment withH2O2. As expected, we confirmed that SMYD2-positive HeLa cells
showed much higher poly(ADP-ribose) signals than SMYD2-negative
HeLa cells, further supporting that PARP1 methylation is likely
to enhance cellular response to H2O2 induced DNA damage
(Figure 5D and E).
Discussion
The poly (ADP-ribose) polymerase (PARP) family of enzymes plays
a critical role in the maintenance of DNA integrity as part of the
base excision pathway of DNA repair. PARP1 is overexpressed in a
variety of cancers, and its expression level has been associated with
overall survival rate of cancer patients, especially in the case of
breast cancer [39,40]. As a novel class of anticancer drugs, more
than 40 preclinical studies or clinical trials of PARP inhibitors are
ongoing [39,41-44]. In this study, we demonstrated that the
oncogenic methyltransferase SMYD2 methylates lysine 528 on
PARP1 and enhance PARP1 poly(ADP-ribosyl)ation enzymatic
activity in cancer cells.
Increased PARP activity is known as one of the mechanisms by
which cancer cells escape from the apoptosis signals induced by
DNA-damaging agents [45]. To maintain genome integrity, cells
possess multiple mechanisms to efficiently repair the different kinds
of DNA damage, including mismatch repair (MMR), base excision
repair (BER), nucleotide excision repair (NER), single-strand break
repair (SSBR), double-strand break repair (DSBR), and so on [46].
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genes responding to DNA damage often promotes human carcino-
genesis [46]. Additionally, inhibiting proteins involved in the DNA
damage response can lead to increase the sensitivity of cancer cells to
chemotherapy. Therefore, studies of the DNA damage response can
elucidate the fundamental mechanisms triggering human carcino-
genesis and provide novel strategies for cancer therapy. In this regard,
since PARP plays an important role in the repair of DNA strand
breaks known to be generated by radiation and chemotherapeutic
drugs, inhibition of elevated PARP enzyme activity in cancer cellshave potential to improve the outcome of cancer chemotherapy or
radiotherapy [47,48].
According to our data, SMYD2 depletion resulted in the reduction
of PARP1 enzymatic activity, suggesting that SMYD2 inhibition
might have also potential to improve cancer chemotherapy. As we
previously reported that SMYD2 was highly overexpressed in
multiple cancer cells and its expression in normal tissues was
significantly low [29], targeting this enzyme may be an ideal strategy
for cancer therapy. In fact, histone methyltransferases have recently
been recognized as good targets for development of cancer therapy,
Neoplasia Vol. 16, No. 3, 2014 SMYD2-dependent PARP1 Methylation in Cancer Cells Piao et al. 263and inhibitors targeting some histone methyltransferases including
SMYD2 have already been reported as candidates of anticancer drugs
[32,49,50]. Although further functional analyses are required, a
SMYD2 inhibitor has great potential to be applied to treat various
types of human cancer.
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Name Origin Certification institution Tested method DNA profile or characteristics
293T human embryonic kidney fibroblast ATCC STR Amelogenin: X CSF1PO: 11, 12 D13S317: 12, 14 D16S539: 9, 13
D5S818: 8, 9 D7S820: 11 THO1: 7, 9.3 TPOX: 11 vWA: 16, 18, 19
HeLa human cervix carcinoma ATCC STR Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11,14 D16S539: 9,11
D5S818: 11,12 D7S820: 10,11 THO1: 8 TPOX: 8 vWA: 15
ATCC; American Type Culture Collection.
A B
Figure W1. SMYD2 mediated PARP1 methylation positively regulates PARP1 enzymatic activity. (A) Two lots of mock-transfected HeLa
cells (Mock stable#1 and #2)and SMYD2-transfected HeLa cells (SMYD2 stable #1 and #2) were lysed and fractionated by SDS-PAGE.
Samples were immunoblotted with anti-HA (Y-11; Santa Cruz)and anti-β-actin (AC-15; SIGMA)antibodies.(B)Number of pADPr positive
cells in Mock stable cells (#1 and #2) and SMYD2 stable cells. Each 1 x 105 Mock stables cells and 1 x 105 SMYD2 stable cells were
seeded into the chamber well, followedby treatment of cells with1 mM H2O2 for 15min.Immunocytochemical analysis showed much
higher poly(ADP-ribose) positivity in SMYD2 stable cells than Mock stable cells.
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